Friday, June 26, 2015

Health Benefits of Coenzyme Q10



I take Coenzyme Q10 for its prevention of muscle pain for statin users:

Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation

According to study published in Biofactors in 2005, fifty consecutive new cardiology clinic patients who were on statin drug therapy (for an average of 28 months) on their initial visit were evaluated for possible adverse statin effects (myalgia, fatigue, dyspnea, memory loss, and peripheral neuropathy). All patients discontinued statin therapy due to side effects and began supplemental CoQ(10) at an average of 240 mg/day upon initial visit.

The patients were then followed for an average of 22 months with 84% of the patients followed now for more than 12 months. The prevalence of patient symptoms on initial visit and on most recent follow-up demonstrated a decrease in fatigue from 84% to 16%, myalgia from 64% to 6%, dyspnea from 58% to 12%, memory loss from 8% to 4% and peripheral neuropathy from 10% to 2%. There were two deaths from lung cancer and one death from aortic stenosis with no strokes or myocardial infarctions. Measurements of heart function either improved or remained stable in the majority of patients.

The researchers concluded that statin-related side effects, including statin cardiomyopathy, are far more common than previously published and are reversible with the combination of statin discontinuation and supplemental CoQ(10).

 But  Coenzyme Q10 has lots of other benefits as well:


Coenzyme Q10 Improves Heart Failure Mortality


Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality in over a decade and should be added to standard treatment, according to lead author Professor Svend Aage Mortensen (Copenhagen, Denmark).

Heart Failure 2013 was held from 25-28 May in Lisbon, Portugal. It is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

Coenzyme Q10 (CoQ10) occurs naturally in the body and is essential to survival. CoQ10 works as an electron carrier in the mitochondria, the powerhouse of the cells, to produce energy and is also a powerful antioxidant. It is the only antioxidant that humans synthesise in the body.

CoQ10 levels are decreased in the heart muscle of patients with heart failure, with the deficiency becoming more pronounced as heart failure severity worsens. Statins are used to treat many patients with heart failure because they block the synthesis of cholesterol, but these drugs also block the synthesis of CoQ10, which further decreases levels in the body.

Double blind controlled trials have shown that CoQ10 improves symptoms, functional capacity and quality of life in patients with heart failure with no side effects. But until now, no trials have been statistically powered to address effects on survival.

The Q-SYMBIO study (2) randomised 420 patients with severe heart failure (New York Heart Association (NYHA) Class III or IV) to CoQ10 or placebo and followed them for 2 years. The primary endpoint was time to first major adverse cardiovascular event (MACE) which included unplanned hospitalisation due to worsening of heart failure, cardiovascular death, urgent cardiac transplantation and mechanical circulatory support. Participating centres were in Denmark, Sweden, Austria, Slovakia, Poland, Hungary, India, Malaysia and Australia.

CoQ10 halved the risk of MACE, with 29 (14%) patients in the CoQ10 group reaching the primary endpoint compared to 55 (25%) patients in the placebo group (hazard ratio=2; p=0.003). CoQ10 also halved the risk of dying from all causes, which occurred in 18 (9%) patients in the CoQ10 group compared to 36 (17%) patients in the placebo group (hazard ratio=2.1; p=0.01).

CoQ10 treated patients had significantly lower cardiovascular mortality (p=0,02) and lower occurrence of hospitalisations for heart failure (p=0.05). There were fewer adverse events in the CoQ10 group compared to the placebo group (p=0.073).

Professor Mortensen said: "CoQ10 is the first medication to improve survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to standard heart failure therapy."

He added: "Other heart failure medications block rather than enhance cellular processes and may have side effects. Supplementation with CoQ10, which is a natural and safe substance, corrects a deficiency in the body and blocks the vicious metabolic cycle in chronic heart failure called the energy starved heart."

CoQ10 is present in food, including red meat, plants and fish, but levels are insufficient to impact on heart failure. CoQ10 is also sold over the counter as a food supplement but Professor Mortensen said: "Food supplements can influence the effect of other medications including anticoagulants and patients should seek advice from their doctor before taking them."

Patients with ischaemic heart disease who use statins could also benefit from CoQ10 supplementation. Professor Mortensen said: "We have no controlled trials demonstrating that statin therapy plus CoQ10 improves mortality more than statins alone. But statins reduce CoQ10, and circulating CoQ10 prevents the oxidation of LDL effectively, so I think ischaemic patients should supplement statin therapy with CoQ10."


Cardiologists examine alternatives to halt high blood pressure


Hypertension expert John Bisognano, M.D., Ph.D.  and Kevin Woolf, M.D., a cardiology fellow at the Medical Center, conducted the most comprehensive review to date of the evidence behind a wide range of non-drug interventions for the treatment of high blood pressure. The review is featured in the September 2011issue of the Journal of Clinical Hypertension.

The shining star among supplements is coenzyme Q10, an enzyme involved in energy production that also acts as an antioxidant. Patients with hypertension tend to have lower levels of the enzyme, and a meta-analysis – an overarching analysis of past studies – found that treatment with coenzyme Q10 supplements significantly reduced blood pressure.

Woolf noted that "Coenzyme Q10 has a pretty profound effect on blood pressure, but whenever research is based on a collection of other data you have to have some skepticism." Woolf said he still thinks the compound is promising.


 

Study shows coenzyme Q10 may prevent migraine


A popular supplement, coenzyme Q10 (CoQ10), may help prevent migraine, according to research presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 – May 1, 2004.

Migraine patients who took 100 mg three times a day of CoQ10--which acts as the body's energy producer--had fewer attacks in three months than those who took a placebo. The participants taking CoQ10 also had fewer days with a headache and fewer days with nausea.

"A lack of cell energy in the brain may be a cause of migraine," said study author Peter S. Sandor, MD, University Hospitals Zurich, Switzerland. "CoQ10 may give a boost to those cells and help prevent migraine."

The study involved 42 people who suffered an average 4.4 migraine attacks per month. Approximately 48 percent of those who took CoQ10 had half as many attacks during the three-month study, while this occurred in only about 14 percent of those taking a placebo.

"We found that coenzyme 10 had a significant effect on reducing migraine," said Sandor. "We also found that the only side effect appeared to be an allergic skin rash in one patient. This compares with side effects of fatigue, weight gain, dry mouth, and other side effects found with other methods to prevent migraine."


Supplemental co-enzyme Q may prevent heart disease in some individuals
New research in The FASEB Journal suggests that low birth weight in rats leads to a reduction in co-enzyme Q in the aorta and that supplemental dosage prevents age-associated damage leading to heart disease
New research involving rats, and published in the December 2014 issue of The FASEB Journal, suggests that if you were born at a low birth weight, supplemental co-enzyme Q (CoQ) may lower your risk for heart disease. This enzyme, which is naturally made in the body, is required to ensure the proper functioning of cell mitochondria and also protects cells from oxidative damage. Feeding low birth weight rat offspring extra CoQ prevented the age-associated damage that causes heart disease. Additionally, the reports shows that CoQ is reduced in white blood cells from low birth weight offspring, and levels of CoQ in the blood can be an indicator of how much damage to the aorta has already occurred.
"We believe our study provides the first steps in the development of a routine diagnostic test for blood coenzyme Q levels which can be used to identify individuals who are at risk of cardiovascular disease later in life," said Jane L. Tarry-Adkins, a researcher involved in the work from the Institute of Metabolic Science at the University of Cambridge Metabolic Research Laboratories in the United Kingdom. "Additionally, simple co-enzyme Q supplements may be able to lower these individuals risk."
To make their discovery, Tarry-Adkins and colleagues fed pregnant rats either a control diet or a diet that had the same total calories but contained less protein and more carbohydrates. The mothers fed the low protein diet had pups which had a low birth weight but grew quickly when suckled by a control fed mother. Researchers examined the aorta from the rats which were born small and grew very quickly after birth and showed that their cells aged more quickly than those from the normal birth weight offspring and that this was associated with a deficit in co-enzyme Q, in both the aorta and in the blood compared to the normal birth weight rats. Administering extra coenzyme Q in their diet from weaning prevented the accelerated aging of and damage to their aortas.
"Coenzyme Q is in the drug store now, but if you think that what you buy is going to keep you from having a heart attack or stroke, don't get your hopes up just yet," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This promising research was conducted in rats, and if it also applies to people, still doesn't tell us how much to take, for how long, and if it's safe for these purposes. We've got a long way to go on this one, but so far, so good!"

Coenzyme Q10 helps veterans battle Gulf War illness symptoms
Eighty percent of treated veterans improved physical function
Roughly one-third of the 700,000 United States troops who fought in the 1990-1991 Persian Gulf War have subsequently developed a distinct set of chronic health problems, dubbed Gulf War illness. Their symptoms, from fatigue, muscle pain and weakness to decreased cognitive function and gastrointestinal and skin problems, persist decades after the conflict.
In a study published in the Nov. 1 issue of Neural Computation, researchers at the University of California, San Diego School of Medicine report that a high quality brand of coenzyme Q10 (CoQ10) – a compound commonly sold as a dietary supplement – provides health benefits to persons suffering from Gulf War illness symptoms.
Forty-six United States Gulf War veterans participated in the randomized, double-blind, placebo-controlled study. Each veteran had been diagnosed with Gulf War illness.
"Gulf War illness is not the same as post-traumatic stress disorder or traumatic brain injury, signature illnesses of later deployments, which are caused by psychological and mechanical injury, respectively," said Beatrice Golomb, MD, PhD, professor of medicine at UC San Diego School of Medicine and principal investigator on the study. "Evidence instead links Gulf War illness to chemical exposures, such as pesticides or pills given to soldiers to protect them from possible nerve agents. These chemicals can damage mitochondria, which generate the energy our cells need to do their jobs. When these powerhouses of the cells are disrupted, it can produce symptoms compatible with those seen in Gulf War illness."
The connection to chemical and toxin exposures is fortified by evidence of mitochondrial problems in affected veterans, said Golomb, as well as evidence showing those veterans who became ill are significantly more likely than others to harbor genetic variants that render their enzymes less effective at detoxifying these chemicals.
CoQ10 is a fat-soluble antioxidant made by the body to support basic cell functions, including directly assisting mitochondrial energy production. Over a course of three and a half months, the veterans in the study received a pill form of either CoQ10 or a placebo. Researchers found 80 percent of those who received 100mg of CoQ10 had improvement in physical function. The degree of improvement correlated to the degree in which CoQ10 levels in the blood increased.
The researchers reported that Gulf War illness symptoms like headaches, fatigue with exertion, irritability, recall problems and muscle pain also improved.
"The statistical significance of these benefits, despite the small sample size, underscores the large magnitude of the effects," Golomb said. "Mounting evidence suggests findings in Gulf War illness are relevant to toxin-induced health problems in the civilian sector, so what we learn by studying health challenges of these veterans, will likely benefit others."
Golomb and colleagues are seeking additional funding to test a more complete "mitochondrial cocktail," which combines CoQ10 with additional nutrients that support cell energy and reduce oxidative damage to cells.

Co-Q10 deficiency may relate to statin drugs, diabetes risk


A laboratory study has shown for the first time that coenzyme Q10 offsets cellular changes that may be linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.

Statins are some of the most widely prescribed drugs in the world, able to reduce LDL, or “bad” cholesterol levels, and the risk of heart attacks or other cardiovascular events. However, their role in raising the risk of diabetes has only been observed and studied in recent years.

The possibility of thousands of statin-induced diabetics is a growing concern, and led last year to new labeling and warnings by the Food and Drug Administration about the drugs, especially when taken at higher dosage levels.

The findings of the new research were published as a rapid communication in Metabolic Syndrome and Related Disorders, and offer another clue to a possible causative mechanism of this problem.

Pharmacy researchers at Oregon State University who authored the study said the findings were made only in laboratory analysis of cells, and more work needs to be done with animal and ultimately human studies before recommending the use of coenzyme Q10 to help address this concern.

“A number of large, randomized clinical trials have now shown that use of statins can increase the risk of developing type-2 diabetes by about 9 percent,” said Matthew K. Ito, an OSU professor of pharmacy and president-elect of the National Lipid Association.

“This is fairly serious, especially if you are in the large group of patients who have not yet had a cardiovascular event, but just take statin drugs to lower your risks of heart disease,” Ito said.

A suspect in this issue has been altered levels of a protein called GLUT4, which is part of the cellular response mechanism, along with insulin, that helps to control blood sugar levels. A reduced expression of GLUT4 contributes to insulin resistance and the onset of type-2 diabetes, and can be caused by the use of some statin drugs.

The statins that reduce cholesterol production also reduce levels of coenzyme Q10, research has shown. Coenzyme Q10 is needed in cells to help create energy and perform other important functions. And this study showed in laboratory analysis that if coenzyme Q10 is supplemented to cells, it prevents the reduction in GLUT4 induced by the statins.

Not all statin drugs, however, appear to cause a reduction in GLUT4.

The problems were found with one statin, simvastatin, that is “lipophilic,” which means it can more easily move through the cell membrane. Some of the most commonly used statins are lipophilic, including simvastatin, atorvastatin, and lovastatin. All of these statins are now available as generic drugs, and high dosage levels have been most often linked with the increase in diabetes.


Coenzyme Q10 and Breast Cancer

Aa reportes in the journal Molecular Aspects of Medicine an open-label (nonblinded), uncontrolled clinical study in Denmark followed 32 breast cancer patients for 18 months.[4] The disease in these patients had spread to the axillary lymph nodes, and an unreported number had distant metastases. The patients received antioxidant supplementation (vitamin C, vitamin E, and beta carotene), other vitamins and trace minerals, essential fatty acids, and coenzyme Q10 (at a dose of 90 mg/day), in addition to standard therapy (surgery, radiation therapy, and chemotherapy, with or without tamoxifen).

The patients were seen every 3 months to monitor disease status (progressive disease or recurrence), and, if there was a suspicion of recurrence, mammography, bone scan, x-ray, or biopsy was performed. The survival rate for the study period was 100% (4 deaths were expected). Six patients were reported to show some evidence of remission; however, incomplete clinical data were provided, and information suggestive of remission was presented for only 3 of the 6 patients. None of the 6 patients had evidence of further metastases. For all 32 patients, decreased use of painkillers, improved quality of life, and an absence of weight loss were reported. Whether painkiller use and quality of life were measured objectively (e.g., from pharmacy records and validated questionnaires, respectively) or subjectively (from patient self-reports) was not specified.

In a follow-up of the above study reported in Biochemical and Biophysical Research Communications, 1 of the 6 patients with a reported remission and a new patient were treated for several months with higher doses of coenzyme Q10 (390 and 300 mg/day, respectively). Surgical removal of the primary breast tumor in both patients had been incomplete. After 3 to 4 months of high-level coenzyme Q10 supplementation, both patients appeared to experience complete regression of their residual breast tumors (assessed by clinical examination and mammography).. In the follow-up study report, the researchers noted that all 32 patients from the original study remained alive at 24 months of observation, whereas 6 deaths had been expected.

In another report in Biochemical and Biophysical Research Communications,  of by the same investigators, 3 breast cancer patients were followed for a total of 3 to 5 years on high-dose coenzyme Q10 (390 mg/day). One patient had complete remission of liver metastases (determined by clinical examination and ultrasonography), another had remission of a tumor that had spread to the chest wall (determined by clinical examination and chest x-ray), and the third patient had no microscopic evidence of remaining tumor after a mastectomy (determined by biopsy of the tumor bed).

No comments: